<DOC>
	<DOCNO>NCT02260986</DOCNO>
	<brief_summary>The purpose demonstrate efficacy long term safety dupilumab combination topical corticosteroid patient moderate severe AD .</brief_summary>
	<brief_title>Study Assess Efficacy Long-term Safety Dupilumab ( REGN668/SAR231893 ) Adult Patients With Moderate-to-Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Key 1 . Chronic atopic dermatitis ( AD ) present least 3 year screen visit 2 . Documented recent history ( within 6 month screen visit ) inadequate response sufficient course outpatient treatment topical AD medication ( ) . Key 1 . Participation prior dupilumab clinical trial 2 . Important side effect topical medication ( eg , intolerance treatment , hypersensitivity reaction , significant skin atrophy , systemic effect ) , assess investigator treat physician 3 . Having use follow treatment within 4 week baseline visit , condition , opinion investigator , likely require treatment ( ) first 2 week study treatment : 1 . Immunosuppressive/immunomodulating drug ( eg , systemic steroid , cyclosporine , mycophenolatemofetil , Janus kinase inhibitor , IFNÎ³ , azathioprine , methotrexate , etc ) 2 . Phototherapy AD 4 . Treatment live ( attenuate ) vaccine within 12 week baseline visit 5 . History human immunodeficiency virus ( HIV ) infection positive HIV serology screen 6 . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) , hepatitis C antibody screen visit 7 . Active acute infection require systemic treatment within 2 week baseline visit 8 . Known suspected history immunosuppression 9 . Pregnant breastfeed woman , plan become pregnant breastfeed patient 's participation study Note : The eligibility criterion list intend contain consideration relevant patient 's potential participation clinical trial therefore inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>